International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.

The subject material appropriate for submission includes:

? Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.

? Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.

? Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.

? Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.

? Agents that activate genes or modify transcription and translation within the immune response.

? Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.

? Production, function and regulation of cytokines and their receptors.

? Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.

《International Immunopharmacology》是一本由ELSEVIER出版商出版的专业医学期刊，该刊创刊于2001年，刊期Monthly，该刊已被国际权威数据库SCI、SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 2区，小类学科：药学 2区；免疫学 3区；在JCR（Journal Citation Reports）分区等级为Q1。该刊发文范围涵盖免疫学等领域，旨在及时、准确、全面地报道国内外免疫学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为5.714，平均审稿速度约2.7个月。